Toronto Sunnybrook Hospital

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Alzheimer disease1 trial
• Childhood cancers1 trial
• Coronary artery disease1 trial
• Melanoma1 trial

Phase

• Phase 36 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Daiichi Sankyo2 trials
• Akeso1 trial
• Biogen1 trial
• Janssen Research & Development, LLC1 trial
• Pierre Fabre Medicament1 trial

Running trials

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Active, not recruiting

  A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

  NCT04974398· Phase 3· Akeso· Source

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source